Sarepta Therapeutics (SRPT) Tops Q3 EPS by 21c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($1.14), $0.21 better than the analyst estimate of ($1.35). Revenue for the quarter came in at $99 million versus the consensus estimate of $98.34 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Goldman Sachs Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Sell, 'Liquidity and capital tightness'
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance